University of Southern California: Melanoma trials

The registry lists 17 Melanoma studies with University of Southern California as lead sponsor. 2 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 6Phase 2 8No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingNCT07838974Phase 1
• Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular CancerNot yet recruitingNCT07836712Phase 2
• 7T MRI Scan for the Early Detection of Melanoma Brain MetastasesTerminatedNCT04941430Not applicable
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesCompletedNCT04752267Early Phase 1
• In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsActive, not recruitingNCT04616248Phase 1
• Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain MetastasesTerminatedNCT03698162Not applicable
• Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous MelanomaTerminatedNCT02968680Phase 1
• Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00334776Phase 2
• Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With MelanomaTerminatedNCT00184067Phase 2
• Vaccine Therapy in Treating Patients With Stage IIC-IV MelanomaCompletedNCT00085189Phase 2
• Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaCompletedNCT00031733Phase 2
• Novel Adjuvants for Peptide-Based Melanoma VaccinesCompletedNCT00028431Phase 1
• Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During SurgeryCompletedNCT00025181Phase 1
• Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV MelanomaTerminatedNCT00006113Phase 2
• Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaTerminatedNCT00005841Phase 1
• Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003339Phase 2
• Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by SurgeryCompletedNCT00003274Phase 2